The demand for highly selective and sensitive LC-MS bioanalytical assays in support of research and development of next-generation oligonucleotide therapies has greatly increased. The work described herein uses SPE, RP-UPLC with the sub-2-μm ACQUITY PREMIER Oligonucleotide C18 Column, and tandem-quadrupole MS for detection and quantification of oligodeoxythymidines and the fully phosphorothioated oligonucleotide antisense therapy, GEM91.
Title | Format | File Size |
---|---|---|
Download PDF | 1270.94kB |